Clinical trials: Amyloidosis Cardiac
HCM - Hypertrophic Cardiomyopathy, Anderson Fabry Disease
Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes
This observational study aims to evaluate myocardial perfusion abnormalities using quantitative and qualitative cardiac magnetic resonance (CMR) perfusion imaging in patients with hypertrophic cardiomyopathy (HCM) phenotypes…
- Conditions
- HCM - Hypertrophic Cardiomyopathy, Anderson Fabry Disease, Cardiac Magnetic Resonance Imaging, Amyloid Cardiomyopathy
- Trial name
- MyoPerf-HCM (NCT07382128)
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Amyloid Cardiomyopathy
Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy
This study aims to evaluate the safety and effectiveness of Enavogliflozin 0.3 mg, an SGLT2 inhibitor, in patients with amyloid cardiomyopathy.
- Trial name
- EMPACT (NCT07240844)
- Testing
- Enavogliflozin 0.3mg
- Where
- 2 sites in South Korea
- Volunteers
- 68 people
- Sponsor
- Seoul St. Mary's Hospital
Plaque, Atherosclerotic Disease
BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population
The BioImage Study is a study of the characteristics of subclinical cardiovascular disease, as measured by imaging modalities, unsupervised circulating biomarker measurements, and risk factors that predict progression to overt…
- Conditions
- Plaque, Atherosclerotic Disease, Heart Disease, Stroke
- Trial name
- NCT00738725
- Where
- 2 sites in United States
- Volunteers
- 7,687 people, healthy volunteers welcome
- Sponsor
- BG Medicine, Inc
Heart Failure
Heart Failure: Don't Forget the Role of Amyloidosis
Heart failure is defined as the inability of the heart to provide sufficient output to meet the needs of the body. It can occur in the course of a myocardial infarction, angina pectoris, hypertension, etc.
- Trial name
- TEAM-HF (NCT05501847)
- Testing
- Patient with no ventricular hypertrophy
- Where
- 2 sites in Guadeloupe, Martinique
- Volunteers
- 446 people
- Sponsor
- University Hospital Center of Martinique
Amyloidosis Cardiac, Virtual Reality
Virtual Reality Assisted Patient Empowerment: Diagnose ATTR-Amyloidosis And Start Treatment
ATTR amyloidosis is a serious condition with significant morbidity and mortality. In Germany, there are numerous unreported cases of untreated patients, and diagnosing and initiating treatment often requires multiple specialized…
- Trial name
- VRAP-DAAST (NCT05938218)
- Testing
- Intervention
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Transthyretin Amyloidosis With Cardiomyopathy
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
The purpose of this study is to: Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events Evaluate the efficacy of nucresiran compared to placebo on additional…
- Trial name
- NCT07052903
- Testing
- Nucresiran, Sterile Normal Saline (0.9% NaCl)
- Where
- 266 sites in United States, Argentina and 34 more
- Volunteers
- 1,750 people
- Sponsor
- Alnylam Pharmaceuticals
Coronary Artery Disease
ELUCIDATE FFRct Study
The goal of this study is to evaluate the diagnostic accuracy of a novel plaque-based coronary CT angiography (CCTA) fractional flow reserve (FFRct) software device for the estimation of invasive fractional flow reserve (FFR).
- Trial name
- NCT06018194
- Testing
- ElucidVivo
- Where
- 8 sites in United States
- Volunteers
- 439 people
- Sponsor
- Elucid Bioimaging Inc.
Coronary Atherosclerosis, Inflammation
Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients
In this study, we, the investigators at National Taiwan University Hospital, will evaluate the efficacy of pharmacological therapy targeted to reduce insulin resistance (pioglitazone) on the progression and compositional change…
- Conditions
- Coronary Atherosclerosis, Inflammation, Coronary Heart Disease
- Trial name
- NCT00155350
- Testing
- pioglitazone
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
Transthyretin Amyloidosis, Transthyretin Amyloidosis With Cardiomyopathy
Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations
The aim of this observational cohort study is to characterise use of eplontersen in patients with prior liver transplant or with pre-existing severe hepatic impairment, as well as to assess long-term safety among all new users of…
- Conditions
- Transthyretin Amyloidosis, Transthyretin Amyloidosis With Cardiomyopathy, Transthyretin Amyloidosis With Polyneuropathy
- Trial name
- sTTRing (NCT07654855)
- Testing
- None ( observational study )
- Where
- 6 sites in United States, Canada and 4 more
- Volunteers
- 320 people
- Sponsor
- AstraZeneca